parbendazole has been researched along with Infections, Rhabdoviridae in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alain, T; Arulanandam, R; Atkins, H; Babawy, A; Batenchuk, C; Bell, JC; Chen, A; Conrad, DP; Cox, J; Davis, C; De Silva, N; Diallo, JS; Falls, T; Forbes, NE; Garcia, V; Garson, K; Hamill, J; Ilkow, C; Karmacharya, R; Krishnan, R; Kærn, M; Le Boeuf, F; Sinha, A; Sonenberg, N; Vanderhyden, B; Varette, O; Waite, K; Weinstein, E; Zakaria, C | 1 |
1 other study(ies) available for parbendazole and Infections, Rhabdoviridae
| Article | Year |
|---|---|
Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing.
Topics: Albendazole; Animals; Benzimidazoles; Bystander Effect; Cell Line; Cell Line, Tumor; Chlorocebus aethiops; Colchicine; Cytokines; HT29 Cells; Humans; Interferon Type I; Mice; Microtubules; Nocodazole; Oncolytic Virotherapy; Oncolytic Viruses; Protein Biosynthesis; Rhabdoviridae; Rhabdoviridae Infections; RNA, Messenger; Tubulin Modulators; Vero Cells; Vinblastine; Vinorelbine | 2015 |